335 related articles for article (PubMed ID: 27348587)
1. Activation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegeneration.
Brahmachari S; Ge P; Lee SH; Kim D; Karuppagounder SS; Kumar M; Mao X; Shin JH; Lee Y; Pletnikova O; Troncoso JC; Dawson VL; Dawson TM; Ko HS
J Clin Invest; 2016 Aug; 126(8):2970-88. PubMed ID: 27348587
[TBL] [Abstract][Full Text] [Related]
2. c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease.
Mahul-Mellier AL; Fauvet B; Gysbers A; Dikiy I; Oueslati A; Georgeon S; Lamontanara AJ; Bisquertt A; Eliezer D; Masliah E; Halliday G; Hantschel O; Lashuel HA
Hum Mol Genet; 2014 Jun; 23(11):2858-79. PubMed ID: 24412932
[TBL] [Abstract][Full Text] [Related]
3. The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson's disease mouse model.
Lee S; Kim S; Park YJ; Yun SP; Kwon SH; Kim D; Kim DY; Shin JS; Cho DJ; Lee GY; Ju HS; Yun HJ; Park JH; Kim WR; Jung EA; Lee S; Ko HS
Hum Mol Genet; 2018 Jul; 27(13):2344-2356. PubMed ID: 29897434
[TBL] [Abstract][Full Text] [Related]
4. α-Synucleinopathy associated c-Abl activation causes p53-dependent autophagy impairment.
Karim MR; Liao EE; Kim J; Meints J; Martinez HM; Pletnikova O; Troncoso JC; Lee MK
Mol Neurodegener; 2020 Apr; 15(1):27. PubMed ID: 32299471
[TBL] [Abstract][Full Text] [Related]
5. Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein: a progressive neurodegenerative model of diffuse Lewy body disease.
Zhou W; Milder JB; Freed CR
J Biol Chem; 2008 Apr; 283(15):9863-70. PubMed ID: 18238775
[TBL] [Abstract][Full Text] [Related]
6. Nilotinib Fails to Prevent Synucleinopathy and Cell Loss in a Mouse Model of Multiple System Atrophy.
Lopez-Cuina M; Guerin PA; Canron MH; Delamarre A; Dehay B; Bezard E; Meissner WG; Fernagut PO
Mov Disord; 2020 Jul; 35(7):1163-1172. PubMed ID: 32291831
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions.
Paleologou KE; Oueslati A; Shakked G; Rospigliosi CC; Kim HY; Lamberto GR; Fernandez CO; Schmid A; Chegini F; Gai WP; Chiappe D; Moniatte M; Schneider BL; Aebischer P; Eliezer D; Zweckstetter M; Masliah E; Lashuel HA
J Neurosci; 2010 Mar; 30(9):3184-98. PubMed ID: 20203178
[TBL] [Abstract][Full Text] [Related]
8. The c-Abl inhibitor IkT-148009 suppresses neurodegeneration in mouse models of heritable and sporadic Parkinson's disease.
Karuppagounder SS; Wang H; Kelly T; Rush R; Nguyen R; Bisen S; Yamashita Y; Sloan N; Dang B; Sigmon A; Lee HW; Marino Lee S; Watkins L; Kim E; Brahmachari S; Kumar M; Werner MH; Dawson TM; Dawson VL
Sci Transl Med; 2023 Jan; 15(679):eabp9352. PubMed ID: 36652533
[TBL] [Abstract][Full Text] [Related]
9. Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?
Fujita M; Sekigawa A; Sekiyama K; Sugama S; Hashimoto M
J Neurol; 2009 Aug; 256 Suppl 3():286-92. PubMed ID: 19711118
[TBL] [Abstract][Full Text] [Related]
10. Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity.
Price DL; Rockenstein E; Ubhi K; Phung V; MacLean-Lewis N; Askay D; Cartier A; Spencer B; Patrick C; Desplats P; Ellisman MH; Masliah E
PLoS One; 2010 Nov; 5(11):e14020. PubMed ID: 21103359
[TBL] [Abstract][Full Text] [Related]
11. A Novel, Selective c-Abl Inhibitor, Compound 5, Prevents Neurodegeneration in Parkinson's Disease.
Kwon SH; Kim S; Park AY; Lee S; Gadhe CG; Seo BA; Park JS; Jo S; Oh Y; Kweon SH; Ma SX; Kim WR; Kim M; Kim H; Kim JE; Lee S; Lee J; Ko HS
J Med Chem; 2021 Oct; 64(20):15091-15110. PubMed ID: 34583507
[TBL] [Abstract][Full Text] [Related]
12. Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models.
Hebron ML; Lonskaya I; Moussa CE
Hum Mol Genet; 2013 Aug; 22(16):3315-28. PubMed ID: 23666528
[TBL] [Abstract][Full Text] [Related]
13. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
[TBL] [Abstract][Full Text] [Related]
14. Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2.
Daher JP; Pletnikova O; Biskup S; Musso A; Gellhaar S; Galter D; Troncoso JC; Lee MK; Dawson TM; Dawson VL; Moore DJ
Hum Mol Genet; 2012 Jun; 21(11):2420-31. PubMed ID: 22357653
[TBL] [Abstract][Full Text] [Related]
15. Distinct region-specific alpha-synuclein oligomers in A53T transgenic mice: implications for neurodegeneration.
Tsika E; Moysidou M; Guo J; Cushman M; Gannon P; Sandaltzopoulos R; Giasson BI; Krainc D; Ischiropoulos H; Mazzulli JR
J Neurosci; 2010 Mar; 30(9):3409-18. PubMed ID: 20203200
[TBL] [Abstract][Full Text] [Related]
16. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
Mehra S; Sahay S; Maji SK
Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
[TBL] [Abstract][Full Text] [Related]
17. Trans-synaptic and retrograde axonal spread of Lewy pathology following pre-formed fibril injection in an in vivo A53T alpha-synuclein mouse model of synucleinopathy.
Schaser AJ; Stackhouse TL; Weston LJ; Kerstein PC; Osterberg VR; López CS; Dickson DW; Luk KC; Meshul CK; Woltjer RL; Unni VK
Acta Neuropathol Commun; 2020 Aug; 8(1):150. PubMed ID: 32859276
[TBL] [Abstract][Full Text] [Related]
18. Distinct Effects of Familial Parkinson's Disease-Associated Mutations on α-Synuclein Phase Separation and Amyloid Aggregation.
Xu B; Fan F; Liu Y; Liu Y; Zhou L; Yu H
Biomolecules; 2023 Apr; 13(5):. PubMed ID: 37238596
[TBL] [Abstract][Full Text] [Related]
19. Inclusion body formation and neurodegeneration are parkin independent in a mouse model of alpha-synucleinopathy.
von Coelln R; Thomas B; Andrabi SA; Lim KL; Savitt JM; Saffary R; Stirling W; Bruno K; Hess EJ; Lee MK; Dawson VL; Dawson TM
J Neurosci; 2006 Apr; 26(14):3685-96. PubMed ID: 16597723
[TBL] [Abstract][Full Text] [Related]
20. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.
Oliveras-Salvá M; Van der Perren A; Casadei N; Stroobants S; Nuber S; D'Hooge R; Van den Haute C; Baekelandt V
Mol Neurodegener; 2013 Nov; 8():44. PubMed ID: 24267638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
